Medicine, St. Louis, Mo.) 17-Hydroxycorticosteroids Of

Total Page:16

File Type:pdf, Size:1020Kb

Medicine, St. Louis, Mo.) 17-Hydroxycorticosteroids Of BINDING OF CORTICOSTEROIDS BY PLASMA PROTEINS. III. THE BINDING OF CORTICOSTEROID AND RELATED HORMONES BY HUMAN PLASMA AND PLASMA PROTEIN FRAC- TIONS AS MEASURED BY EQUILIBRIUM DIALYSIS 1, 2 BY WILLIAM H. DAUGHADAY WITH THE TECHNICAL ASSISTANCE OF IDA KOZAK (From the Metabolism Dizision, Department of Medicine, Washington University School of Medicine, St. Louis, Mo.) (Submitted for publication September 30, 1957; accepted December 5, 1957) The physical state of the corticosteroid hor- drawn, although little loss of binding affinity occurred mones in human plasma has been under investi- after storage at -10° C. The conditions of dialysis were the same as previously reported (2). Usually 10 ml. of gation in this laboratory. Dialysis equilibrium ex- plasma in a cellophane bag (Visking nojax, 18/32 casing) periments have been reported which show that the was dialyzed against 40 ml. of Krebs phosphosaline buf- 17-hydroxycorticosteroids of plasma are bound to fer, pH 7.4 (4), in a large test tube. Where a high de- plasma proteins to an extent of more than 90 per gree of binding was anticipated, 80 ml. of buffer was cent (2). Of the plasma protein fractions tested used. In several experiments where the amount of plasma or plasma protein fraction was limited, 5 ml. of protein for their cortisol binding power with high con- solution was dialyzed against 40 ml. of buffer. The ra- centrations of cortisol, albumin had the greatest dioactive and nonradioactive steroids were included in binding affinity. The importance of albumin was the dialysis buffer by diluting an alcoholic solution of apparently further supported by equilibrium pa- the steroids with buffer. The final alcohol concentration per electrophoresis conducted with cortisol-4-C14 of alcohol was below 1 per cent in all experiments. Although equilibrium conditions are reached for all prac- in which the greatest concentration of radioactivity tical purposes in 24 hours, the dialyses were allowed to was associated with the albumin component of continue for 48 hours at 40 C. plasma (3). It was difficult, however, to ex- The buffer was separated from the plasma at the con- plain the greater binding of 17-hydroxycortico- clusion of the dialysis and the volume measured. It was steroids in plasma than that which occurred in then extracted three times with ethyl acetate using 1.0, 1.0, and 0.5 volumes of solvent. The extracts were equilibrium dialysis experiments using cortisol pooled and evaporated to dryness in a boiling flask. and albumin. This discrepancy has prompted a The protein concentration of the plasma was measured thorough reinvestigation of corticosteroid binding by a biuret method (5). The plasma was extracted a at physiologic levels of hormone by plasma and single time with five volumes of chloroform in a stoppered plasma protein fractions. Progress has been tube. Emulsions were broken by centrifugation and the steroids, supernatant plasma was removed by suction. Anhy- greatly aided by the availability of labeled drous sodium sulfate was used to dry the extract and an greatly simplifying the analytical techniques. Evi- aliquot, usually 20 ml., was evaporated to dryness in a dence indicating the presence of two independent small boiling flask. corticosteroid binding systems in plasma is pre- The steroid residues were carefully dissolved in 1.5 sented in this paper. ml. of ethyl alcohol and then 0.5 ml. of 8 per cent glu- cose was added and mixed well. Duplicate aliquots of this solution were pipetted into tared brass cups con- METHODS taining disks of lens paper. The cups were reweighed Heparinized blood was obtained from normal adult after drying under an infrared light. Radioactivity was laboratory workers and students in midmorning fol- determined with a windowless gas flow counter operat- lowing a light breakfast. In most experiments plasma ing in the proportional range. The observed counts were was used for binding studies on the day that it was corrected to infinite thinness using an experimentally determined curve prepared with cortisol-4-C'4. The glu- 'Reported in part at the Annual Meeting of the Cen- cose provides a smooth adhesive glaze. Recovery of tral Society for Clinical Research, November, 1956 (1). added cortisol-4-C14, using these extraction and counting 2This investigation was supported by a research techniques, has varied between 90 and 105 per cent. grant, C-255, from the National Institute of Arthritis and Control experiments in the absence of plasma have failed Metabolic Diseases of the National Institutes of Health, to show significant adsorption of the labeled steroids on Public Health Service. the glass or dialyzing membranes. 511 512 WILLIAM H. DAUGHADAY This expression has the form of an association constant but cannot be calculated in molecular terms because the molecular weights of the binding proteins other than al- 1.0- bumin are unknown. For most of the steroids studied C K % & '. ..-~-A - -.- -A- --- - Estrone is not constant for human plasma but is greatly influenced 'I by the concentrations of the steroids in the system. K UBy '--.-_- Testosterone This simple formulation provides an empiric method for a 0.I- comparing the binding observed with plasma and plasma protein fractions of different protein and steroid con- ai 0 (A Corticost:erone centrations. 0 x Cortisol .L RESULTS I Ii. 0o1- The binding of progesterone-4-Cl, corticoster- ?. one-4-C14, cortisol-4-C04, testosterone-4-C4, and estrone-16-C04 by human plasma has been meas- I I10 100 1000 ured in the presence of different amounts of car- 04. STEROID ADDED rier steroid added to the dialysis equilibrium sys- FIG. 1. CHANGES IN THE BINDING AFFINITY OF NOR- MAL HUMAN PLASMA FOR CORTISOL-4-C14, CORTICOSTER- tem. The changes in combining affinities with in- ONE-4-C4, PROGESTERONE-4-C14, TESTOSTERONE-4-C1, AND creasing concentrations of steroid have been ESTRONE-16-C1 IN THE PRESENCE OF INCREASING plotted on a double logarithmic scale in Figure 1. AMOUNTS OF TOTAL STEROID IN A STANDARD DIALYSIS At the lowest concentrations studied, the two cor- EQUILIBRIUM SYSTEM CONTAINING 10 ML. OF PLASMA AND 80 ML. OF BUFFER ticosteroid hormones (cortisol and corticosterone) are bound nearly completely to the plasma pro- Corticosterone-4-C'4 and cortisol-4-C14, with specific teins. When more steroid is added to the system activities of 1.467 millicuries per millimole, were ob- there is a large decrease in the affinity of binding. tained from the Endocrinology Study Section of the National Institutes of Health. Progesterone-4-C'4, with After a transition phase, further additions of a specific activity of 1.63 millicuries per millimole, was cortisol and corticosterone make relatively little prepared by Tracerlab, Boston, Massachusetts. Estrone- difference in the measured affinity. The behavior 16-C" and estradiol-16-C1', with specific activities of 0.74 of estrone in comparable experiments is quite millicuries per millimole, were supplied by Charles E. different in that the binding affinity is not signifi- Frost Co., Montreal. Testosterone4-C'4, with a specific activity of 1.44 millicuries per millimole, was obtained cantly influenced by the amount of estrone added from the Ray Chem Laboratories, Elmsford, New York. to the system. The results with progesterone The nonradioactive steroids were either in crystalline form or as a fine crystalline suspension in talc (U. S. P. Reference Standard Steroids). The steroids were ex- tracted from the latter preparations with ethyl alcohol 90- and diluted to the desired concentration with the dialysis buffer. dm%-WV- The combining affinity of a protein solution for a given az I 0 steroid under the specified conditions of protein and a steroid concentration has been expressed in the follow- *- 70- (140) z ing way: hi Bound steroid 60. C (combining affinity) =-.Unbound steroid X protein Unbound steroid: This is the steroid which is not 90-1 bound to protein as determined by the steroid con- centration of the buffer corrected for the lower wa- ter content within the dialysis bag. 6 S&to o io 4o 50 *!0SO 70A O Bound steroid: The steroid bound to protein is the pV/ 100 ML. PLASMA difference between the concentration of total steroid CORTIOLS within the dialysis bag and the concentration of free FIG. 2. THE CALCULATED CHANGES IN THE PERCENT- steroid. AGE OF CORTISOL BINDING BY HUMAN PLASMA PLOTTED Protein: The concentration of protein within the bag AGAINST THE TOTAL CORTISOL CONCENTRATION OF PLASMA after dialysis is expressed as milligrams per milli- These calculations were made from the data sum- liter. marized in Figure 1. BINDING OF CORTICOSTEROID HORMONES BY PLASMA 513 TABLE I A comparison of the ability of related steroids to inhibit the binding of cortisol-4-C4 * F-4-C4t Competing steroid Amount Plasma Free Bound Protein Ct pg. cpm/ml. cpm/ml. mg./ml. None 0 A 4.1 297 66.1 1.095 B 3.3 262 60.7 1.33 D 3.7 245 61.5 1.08 9a-fluorocortisol 10 B 5.9 254 63.7 0.68 10.2 D 4.7 252 62.8 0.86 d, 1-aldosterone 10 C 5.8 225 60.3 0.64 3a, 11,, 17a, 21-tetrahydroxy- 10 A 7.2 248 67.1 0.51 pregnane-20-one 11i, 17a, 21-trihydroxy- 10 A 9.3 237 68.8 0.37 pregnane-3, 20-dione Progesterone 8.7 D 12.4 208 61.3 0.27 Cortisone 10 B 15.9 205 59.9 0.22 1 la-hydroxycortisol 10 B 15.2 222 61.2 0.24 11-desoxycorticosterone 10 A 25 179 71.1 0.10 17a-hydroxyprogesterone 9.14 C 25.5 138.5 61.7 0.080 Prednisolone 9.97 C 29.5 125.7 60.8 0.070 11-desoxycortisol (Compound S) 10 B 36.9 121.1 60.6 0.054 21-desoxycortisol 9.57 C 29.1 97.8 61.4 0.055 Corticosterone 10 A 32 113 66 0.053 2-methylcortisol 10.4 D 32 106 64 0.053 Cortisol 10 A 34.4 110.6 69 0.048 10 B 38.5 106.5 63 0.044 10 C 32.3 92.3 64 0.045 10 D 31.5 98.0 61.4 0.051 *Conditions-Ten ml.
Recommended publications
  • 1970Qureshiocr.Pdf (10.44Mb)
    STUDY INVOLVING METABOLISM OF 17-KETOSTEROIDS AND 17-HYDROXYCORTICOSTEROIDS OF HEALTHY YOUNG MEN DURING AMBULATION AND RECUMBENCY A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN NUTRITION IN THE GRADUATE DIVISION OF THE TEXAS WOI\IIAN 'S UNIVERSITY COLLEGE OF HOUSEHOLD ARTS AND SCIENCES BY SANOBER QURESHI I B .Sc. I M.S. DENTON I TEXAS MAY I 1970 ACKNOWLEDGMENTS The author wishes to express her sincere gratitude to those who assisted her with her research problem and with the preparation of this dissertation. To Dr. Pauline Beery Mack, Director of the Texas Woman's University Research Institute, for her invaluable assistance and gui­ dance during the author's entire graduate program, and for help in the preparation of this dissertation; To the National Aeronautics and Space Administration for their support of the research project of which the author's study is a part; To Dr. Elsa A. Dozier for directing the author's s tucly during 1969, and to Dr. Kathryn Montgomery beginning in early 1970, for serving as the immeclia te director of the author while she was working on the completion of the investic;ation and the preparation of this dis- sertation; To Dr. Jessie Bateman, Dean of the College of Household Arts and Sciences, for her assistance in all aspects of the author's graduate program; iii To Dr. Ralph Pyke and Mr. Walter Gilchrist 1 for their ass is­ tance and generous kindness while the author's research program was in progress; To Mr. Eugene Van Hooser 1 for help during various parts of her research program; To Dr.
    [Show full text]
  • 18-Dehydrogenase Deficiency W
    Arch Dis Child: first published as 10.1136/adc.51.8.576 on 1 August 1976. Downloaded from Archives of Disease in Childhood, 1976, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency W. HAMILTON, A. E. McCANDLESS, J. T. IRELAND, and C. E. GRAY From the University Departments of Child Health, Liverpool and Glasgow Hamilton, W., McCandless, A. E., Ireland, J. T., and Gray, C. E. (1976). Archives of Disease in Childhood, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency. Three sibs all presented in the early neonatal period with a salt-losing syndrome. The salt-losing form of congenital adrenal hyperplasia was diagnosed and appropriate treatment with glucocorticosteroids, mineralocorticosteroids, and additional dietary salt started. Although early life was maintained with difficulty, with age all3 children required decreasingamounts ofreplace- ment steroids to maintain normal plasma electrolyte balance. They were reinvestigated at the ages of 15 years and 8 years (twins), when cortisol synthesis and metabolism proved normal, but aldosterone synthesis was blocked by deficiency of 18-dehydro- genase. Rational treatment of these cases of a salt-losing syndrome in which aldo- sterone synthesis alone is blocked due to lack of the enzyme 18-dehydrogenase requires the administration of a mineralocorticosteroid drug only. Since deoxycor- ticosterone (acetate or pivalate) requires intramuscular administration, as life-long therapy oral fludrocortisone is preferable. Although fludrocortisone has glucocorti- coid activity, the 'hydrocortisone equivalent' effect of the small dosage used was un- likely to inhibit either pituitary corticotrophin or growth hormone production. Salt-loss of adrenal origin is recognized as a female external genitalia or macrogenitosomia http://adc.bmj.com/ feature of 3/1-hydroxysteroid dehydrogenase de- praecox in the male.
    [Show full text]
  • Internal Hcpcs Code Description Charge Charge Number Lab 10001 84060 Acid Phosphatase #829642 68.5 10002 82040 Albumin Sera 69.5
    INTERNAL HCPCS CODE DESCRIPTION CHARGE CHARGE NUMBER LAB 10001 84060 ACID PHOSPHATASE #829642 68.5 10002 82040 ALBUMIN SERA 69.5 10003 84075 ALKALINE PHOSPHATASE 52.5 10004 82150 AMYLASE 7 80.5 10009 82088 ALDOSTERONE, SERUM #004374 498 10011 86060 ASO TITER #006031 119.5 10013 84600 ALCOHOL, METHYL #017699 219 10014 87116 AFB CULTURE AND SMEAR/ #183753 165 10015 86901 BLOOD TYPING-RH (D) 23 10016 87206 ACID FAST STAIN #008618 73 10017 82247 TOTAL BILIRUBIN 50.5 10018 86900 BLOOD TYPING-ABO 23 10019 85002 BLEEDING TIME 50.5 10020 84520 BUN 43.5 10022 82607 VITAMIN B-12 115 10026 82310 CALCIUM,TOTAL 39 10027 85025 CBC W/COMP DIFF 69.5 10028 82380 CAROTENE #001529 138.5 10029 82435 CHLORIDE SERUM 80.5 10030 82465 CHOLESTEROL 50.5 10032 82550 CPK, TOTAL 67.5 10033 82565 CREATININE 44.5 10034 82575 CREATININE CLEARANCE #003004 80.5 10035 82378 CEA #002139 169 10036 87070 CULTURE SPUTUM & GRAM STAIN 51.5 10037 82552 CPK ISOENZYMES #002154 123.5 10038 82355 CALCULUS ANALYSIS #120790 142 10039 82382 CATECHOLAMINES,RANDOM URINE #316203 179.5 10040 82533 CORTISOL,TOTAL 175.5 10041 85007 DIFFERENTIAL 22 10044 80162 DIGOXIN/LANOXIN LEVEL 152 10045 80185 DILANTIN, QUANT 105.5 10048 P9016 PRBC'S 326.5 10050 36430 BLOOD ADMINISTRATION 262.5 10051 86022 PLATELETS APHERESIS 1112 10054 83700 ELECTROPHORESIS, LIPOPROTEIN #235036 165 10055 83020 ELECTROPHORESIS, HEMOGLOBIN 82.5 10056 80307 ETHANOL, QUANT. 173.5 10057 87106 FUNGAL ID #390 167 10058 86780 FTA-ABS #006379 118 10059 82746 FOLATE (FOLIC ACID) SERUM 68.5 10062 82941 GASTRIN SERUM #004390 95.5 10063 87205 GRAM STAIN 42 10064 85014 HCT 28 10065 85018 HEMOGLOBIN 28 10066 84702 HCG, QUANT.
    [Show full text]
  • Parotid Fluid Cortisol and Cortisone
    Parotid Fluid Cortisol and Cortisone FRED H. KAIZ and IRA L. SHANNON From the Department of Medicine, Loyola University Stritch School of Medicine, Hines, Illinois 60141 and the Section of Experimental Dentistry, U. S. Air Force School of Aerospace Medicine, Brooks Air Force Base, Texas 78235 A B S T R A C T Parotid fluid corticosteroids, substan- parallels that of plasma after the administration of tially comprised of cortisol and cortisone, were previ- ACTH (1). Parotid fluid-Porter-Silber chromogens are ously demonstrated to rise to far greater levels 4 hr af- also a useful index to adrenocortical suppression by dexa- ter administration of ACTH than they did in the third methasone1 (2) and for the diagnosis of Cushing's trimester of pregnancy, although the plasma total corti- syndrome (3). During pregnancy, despite a two- to costeroid concentrations were similar in these two threefold increase in plasma 17-hydroxycorticosteroids, states. It was therefore suggested that only nonprotein- the parotid fluid corticosteroids rose only minimally bound corticosteroid gains access to parotid fluid. In though significantly (4). Following ACTH treatment, the present study parotid fluid cortisol and cortisone and when plasma corticosteroids were similar to the values plasma dialyzable cortisol concentrations have been found in pregnant women, the parotid fluid corticoids measured in normal men before and 2 hr after 40 U rose to values several times the base line. Because most ACTH, and, in another group, before and after 10 days of the increased plasma 17-hydroxycorticosteroids in of diethystilbestrol (5 mg daily). Total plasma cortisol pregnancy are protein-bound, whereas the acute increase rose from a mean of 6.3 to 17.9 ,ug/100 ml after ACTH following ACTH represents more nonprotein-bound and from 14.6 to 39.4 mg/100 ml after the estrogen.
    [Show full text]
  • Current and Novel Approaches to Children and Young People with Congenital Adrenal Hyperplasia and Adrenal Insufficiency Webb, Emma A.; Krone, Nils
    University of Birmingham Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency Webb, Emma A.; Krone, Nils DOI: 10.1016/j.beem.2015.04.002 License: Other (please specify with Rights Statement) Document Version Peer reviewed version Citation for published version (Harvard): Webb, EA & Krone, N 2015, 'Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency', Best practice & research. Clinical endocrinology & metabolism. https://doi.org/10.1016/j.beem.2015.04.002 Link to publication on Research at Birmingham portal Publisher Rights Statement: NOTICE: this is the author’s version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Webb EA, Krone N, Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency, Best Practice & Research Clinical Endocrinology & Metabolism (2015), doi: 10.1016/j.beem.2015.04.002. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
    [Show full text]
  • Endocrine Test Selection and Interpretation
    The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition Edited by: Delbert A. Fisher, MD Senior Science Officer Quest Diagnostics Nichols Institute Professor Emeritus, Pediatrics and Medicine UCLA School of Medicine Consulting Editors: Wael Salameh, MD, FACP Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute San Juan Capistrano, CA Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Richard W. Furlanetto, MD, PhD Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute Chantilly, VA ©2007 Quest Diagnostics Incorporated. All rights reserved. Fourth Edition Printed in the United States of America Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. All third party marks − ®' and ™' − are the property of their respective owners. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, and information storage and retrieval system, without permission in writing from the publisher. Address inquiries to the Medical Information Department, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130. Previous editions copyrighted in 1996, 1998, and 2004. Re-order # IG1984 Forward Quest Diagnostics Nichols Institute has been
    [Show full text]
  • Composition: Dexamethasone B.P. ---0.5Mg List of Excipients
    Summary of product characteristics (SmPC) 1. NAME OF THE MEDICINAL PRODUCT: DEXAMETHASONE TABLETS 0.5mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Composition: Each uncoated tablet contains: Dexamethasone B.P. ---------0.5mg List of excipients: Aerosil 200, Purified talc, Magnesium stearate, Sodium hydroxyl benzoate (methyl paraben sodium), Dicalcium phosphate, cross carmellose sodium and sodium starch glycolate. 3. PHARMACEUTICAL FORM: A white circular uncoated tablet (Flat Face Bevel Edge) with break line on one side. 4. CLINICAL PARTICULARS: 4.1 Therapeutic Indications: Orally: Palliative treatment of rheumatoid arthritis, rheumatic spondylitis osteoarthritis, polyarthritis, chronic psoriatic arthritis, bursitis, tendinitis, synovitis, fibrositis, mucositis, neuritis, bronchial asthma, rheumatic fever, addision’s disease, waterhouse friderichsen’s syndrome allergies, serum sickness, drug sensitivity. 4.2 Posology and Method of Administration: Posology In general, glucocorticoid dosage depends on the severity of the condition and response of the patient. Under certain circumstances, for instance in stress and changed clinical picture, extra dosage adjustments may be necessary. If no favourable response is noted within a couple of days, glucocorticoid therapy should be discontinued. Adults Usually, daily oral dosages of 0.5 - 10 mg are sufficient. In some patients higher dosages may be temporarily required to control the disease. Once the disease is under control the dosage should be reduced or tapered off to the lowest suitable level under continuous monitoring and observation of the patient. (See Section 4.4) For a short dexamethasone suppression test, 1mg dexamethasone is given at 11 p.m. and plasma cortisol measured the next morning. Patients who do not show a decrease in cortisol can be exposed to a longer test: Page 1 of 8 500 micrograms dexamethasone is given at 6 hourly intervals for 48 hours followed by 2mg every 6 hours for a further 48 hours.
    [Show full text]
  • Supplemental Corticosteroids for Dental Patients with Adrenal
    DENTISTRY & MEDICINE ABSTRACT Background. Dental patients with pri- mary or secondary adrenal insufficiency, or AI, may be A D A at risk of experiencing J ✷ ✷ adrenal crisis during or C N O after invasive procedures. O N I Since the mid-1950s, sup- T T Supplemental I A N U C I U plemental steroids in A N G E D R 3 corticosteroids for rather large doses have TICLE been recommended for patients with AI to prevent adrenal crisis. dental patients with Methods. To evaluate the need for sup- plemental steroids in these patients, the adrenal insufficiency authors searched the literature from 1966 to 2000 using MEDLINE and textbooks for Reconsideration of the information that addressed AI and adrenal crisis in dentistry. Reference lists of rele- problem vant publications and review articles also were examined for information about the topic. CRAIG S. MILLER, D.M.D., M.S.; JAMES W. LITTLE, Results. The review identified only four D.M.D., M.S.; DONALD A. FALACE, D.M.D. reports of purported adrenal crisis in den- tistry. Factors associated with the risk of adrenal crisis included the magnitude of or more than 50 years, medicine and dentistry surgery, the use of general anesthetics, the have appreciated the importance of the adrenal health status and stability of the patient, glands in maintaining physiological integrity. and the degree of pain control. This appreciation grew from studies1,2 in the Conclusions. The limited number of 1930s that demonstrated that adrenocortical reported cases strongly suggests that Finsufficiency was associated with electrolyte disturb- adrenal crisis is a rare event in dentistry, ances, and a decade later3 that cortisol prevented hypo- especially for patients with secondary AI, volemia and circulatory collapse associ- and most routine dental procedures can be ated with adrenalectomy.
    [Show full text]
  • ERS Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children
    Early View Task Force Report ERS guidelines on the diagnosis and treatment of chronic cough in adults and children Alyn H. Morice, Eva Millqvist, Kristina Bieksiene, Surinder S. Birring, Peter Dicpinigaitis, Christian Domingo Ribas, Michele Hilton Boon, Ahmad Kantar, Kefang Lai, Lorcan McGarvey, David Rigau, Imran Satia, Jacky Smith, Woo-Jung Song, Thomy Tonia, Jan W. K. van den Berg, Mirjam J. G. van Manen, Angela Zacharasiewicz Please cite this article as: Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2019; in press (https://doi.org/10.1183/13993003.01136-2019). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2019 ERS guidelines on the diagnosis and treatment of chronic cough in adults and children Alyn H Morice1, Eva Millqvist2, Kristina Bieksiene3, Surinder S Birring4, Peter Dicpinigaitis5, Christian Domingo Ribas6, Michele Hilton Boon7, Ahmad Kantar8, Kefang Lai9*, Lorcan McGarvey10, David Rigau11, Imran Satia12, Jacky Smith13, Woo- Jung Song14**, Thomy Tonia15, Jan WK van den Berg16, Mirjam J. G. van Manen17, Angela Zacharasiewicz18 Affiliations: 1Respiratory Research Group, Hull York Medical School, University of Hull, UK. 2University of Gothenburg, Department of Internal Medicine/Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Sweden. 3Department of Pulmonology, Lithuanian University of Health Sciences, Lithuania.
    [Show full text]
  • O,P'-DDD and Aminoglutethimide R
    Postgrad Med J: first published as 10.1136/pgmj.51.591.35 on 1 January 1975. Downloaded from Postgraduate Medical Journal (January 1975) 51, 35-37. Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide R. D. M. SCOTT M.B., M.R.C.P.E., M.R.C.P. Department of Medicine, Western General Hospital, Edinburgh EH4 2XU Summary tures of several vertebrae. Intravenous pyelography A patient with Cushing's syndrome due to an adreno- showed depression of the left kidney, and left renal cortical carcinoma is described. Treatment of residual arteriography demonstrated an enlarged left adrenal disease and functional metastases was attempted with with several abnormal vessels surrounding it. At o,p'-DDD and later aminoglutethimide. Aminoglute- operation (Mr J. E. Newsam), an adrenal carcinoma thimide in a daily dose of 1 g appeared to have little invading the left renal pedicle was found. Left effect additional to o,p'-DDD. It is important to adrenalectomy and nephrectomy were performed maintain replacement therapy with cortico-steroids with removal of some but not all of the involved throughout the use of these drugs. paraaortic lymph nodes. The diagnosis was confirmed Introduction histologically. The of adrenal carcinoma TABLE 1. Plasma and urinary steroid prognosis inoperable measurements before treatment has altered since the introduction of 1,1-dichloro-2- copyright. (o-chlorophenyl)-2-(p-chlorophenyl)-ethane-o,p'- Plasma 11 -hydroxycorticosteroids DDD-which has been demonstrated to have a (11-OHCS) cytotoxic action on the adrenal cortex (Vilar and at 2300 hr 45 ,g/100 ml Its use has been limited the at 0800 hr 32 ,tg/100 ml Tullner, 1959).
    [Show full text]
  • Ovid Medline(R)
    Supplement 1. Search strategy Database for original search: Ovid Medline(R) 1946 to September Week 1 2014 Databases for update searches: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Date original search conducted: 14 September 2014 Date first update search conducted: 24 February 2016 Date second update search conducted: 31 July 2017 Strategy: 1. Adrenal Cortex Hormones/ 2. Anti-Inflammatory Agents/ 3. Beclomethasone/ 4. Budesonide/ 5. exp Glucocorticoids/ 6. exp Hydroxycorticosteroids/ 7. Pregnenediones/ 8. Triamcinolone Acetonide/ 9. adrenal cortex hormone*.tw,nm. 10. advair*.tw,nm. 11. alvesco*.tw,nm. 12. azmacort*.tw,nm. 13. becl?met*.tw,nm. 14. beclazone*.tw,nm. 15. beclo?ort*.tw,nm. 16. beclovent*.tw,nm. 17. beconase*.tw,nm. 18. becotide*.tw,nm. 19. betamet?asone*.tw,nm. 20. betnesol*.tw,nm. 21. budesonide*.tw,nm. 22. ciclesonide*.tw,nm. 23. clobetasol*.tw,nm. 24. cortiso*.tw,nm. 25. cortodoxone*.tw,nm. 26. corticosteroid*.tw,nm. 27. decadron*.tw,nm. 28. depo medrone*.tw,nm. 29. desoximet?asone*.tw,nm. 30. dexamethasone*.tw,nm. 31. deflazacort*.tw,nm. 32. diflucortolone*.tw,nm. 33. flixotide*.tw,nm. 34. flumethasone*.tw,nm. Supplement 1 - Page 1 of 13 35. flunisolide*.tw,nm. 36. fluocino*.tw,nm. 37. fluocortolone*.tw,nm. 38. fluorometholone*.tw,nm. 39. flurandrenolone*.tw,nm. 40. fluticasone*.tw,nm. 41. glucocortico*.tw,nm. 42. hydrocortisone*.tw,nm. 43. hydroxycorticostero*.tw,nm. 44. hydrocortone*.tw,nm. 45. hydroxypregnenolone*.tw,nm. 46. kenacort*.tw,nm. 47. kenalog*.tw,nm.
    [Show full text]
  • Effect of Aminoglutethimide on Blood Pressure and Steroid Secretion in Patients with Low Renin Essential Hypertension
    Effect of Aminoglutethimide on Blood Pressure and Steroid Secretion in Patients with Low Renin Essential Hypertension Addison A. Taylor, … , John R. Gill Jr., Ronald B. Franklin J Clin Invest. 1978;62(1):162-168. https://doi.org/10.1172/JCI109101. Research Article An inhibitor of adrenal steroid biosynthesis, aminoglutethimide, was administered to seven patients with low renin essential hypertension, and the antihypertensive action of the drug was compared with its effects on adrenal steroid production. In all patients aldosterone concentrations in plasma and urine were within normal limits before the study. Mean arterial pressure was reduced from a pretreatment value of 117±2 (mean±SE) mm Hg to 108±3 mm Hg after 4 days of aminoglutethimide therapy and further to 99±3 mm Hg when drug administration was stopped (usually 21 days). Body weight was also reduced from 81.6±7.2 kg in the control period to 80.6±7.0 kg after 4 days of drug treatment and to 80.1±6.7 kg at the termination of therapy. Plasma renin activity was not significantly increased after 4 days of treatment but had risen to the normal range by the termination of aminoglutethimide therapy. Mean plasma concentrations of deoxycorticosterone and cortisol were unchanged during aminoglutethimide treatment whereas those of 18- hydroxydeoxycorticosterone, progesterone, 17α-hydroxyprogesterone, and 11-deoxycortisol were increased as compared to pretreatment values. In contrast, aminoglutethimide treatment reduced mean plasma aldosterone concentrations to about 30% of control values. Excretion rates of 16β-hydroxydehydroepiandrosterone, 16-oxo-androstenediol, 17- hydroxycorticosteroids and 17-ketosteroids, and the secretion rate of 16β-hydroxydehydroepiandrosterone were not significantly altered by aminoglutethimide treatment whereas the excretion rate of aldosterone was reduced from 3.62±0.5 (mean±SE) in the control period […] Find the latest version: https://jci.me/109101/pdf Effect of Aminoglutethimide on Blood Pressure and Steroid Secretion in Patients with Low Renin Essential Hypertension ADDISON A.
    [Show full text]